Kai KupferschmidtScience's COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.Joining the flood of press releases announcing positive results from COVID-19 vaccine trials, developers of Russia’s Sputnik V vaccine today reported 91.4% efficacy from a second interim analysis of more than 18,000 people, bolstering a claim the team made on 11 November with scant evidence.While the initial report rested on a mere 20 cases of COVID-19 disease, with no details on how they were split between vaccinated and placebo groups, the new analysis is based on 39 cases total, 31 among the vaccinated group versus eight in the much smaller placebo arm. “This is great news not just for Russia, but the world,” Kirill.